Curis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 5.00 M
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.33 Cr
- Revenue Growth 52.98%
- Profit Growth -64.00%
- Ebitda 42.26%
- Net Worth 26.48%
- Total Assets 25.08%
About Curis Lifesciences
Curis Lifesciences Private Limited (CLPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 March 2016 (Eight years and ten months 10 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹12.33 Cr.
Piyush Antala, Dharmesh Patel, Jaimik Patel, and One other member serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ2016PTC086559
-
Company No.
086559
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Mar 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Curis Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyush Antala
|
Director | 23-Mar-2016 | Current |
|
Dharmesh Patel
|
Director | 23-Mar-2016 | Current |
|
Jaimik Patel
|
Director | 23-Mar-2016 | Current |
|
Siddhant Pawasia
|
Director | 23-Mar-2016 | Current |
Financial Performance of Curis Lifesciences.
Curis Lifesciences Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 52.98% increase. The company also saw a substantial fall in profitability, with a 64% decrease in profit. The company's net worth Soared by an impressive increase of 26.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curis Lifesciences?
In 2021, Curis Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹123.25 M
₹0
Charges Breakdown by Lending Institutions
- Others : 12.33 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Apr 2023 | Others | ₹3.50 M | Open |
| 21 Mar 2017 | Others | ₹11.98 Cr | Open |
How Many Employees Work at Curis Lifesciences?
Curis Lifesciences has a workforce of 58 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.